Zydus Lifesciences Ltd has received in-principle approval from the WHO for its Typhoid Vi conjugate vaccine, ZyVac TCV. Eligible for UN procurement, the vaccine targets 6-month to 65-year-olds and addresses high typhoid incidence in India, Africa, and Southeast Asia.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.